BBC3 Recombinant Monoclonal Antibody

BBC3, also known as PUMA (p53 up-regulated modulator of apoptosis), serves as a critical BH3-only protein that functions as a potent inducer of apoptosis. As a direct transcriptional target of p53, BBC3 plays a central role in the intrinsic apoptotic pathway by binding to and neutralizing anti-apoptotic Bcl-2 family members, thereby releasing pro-apoptotic proteins to trigger mitochondrial outer membrane permeabilization. This makes BBC3 a protein of significant interest in cancer research, particularly in studies examining p53-dependent cell death mechanisms and therapeutic resistance.

This recombinant monoclonal antibody, generated from clone 5D4 in rabbit host, offers the consistency and reproducibility that demanding research applications require. Because recombinant antibodies are produced from defined sequences rather than hybridoma-derived sources, you can expect reliable lot-to-lot performance across extended studies, which proves especially valuable when tracking subtle changes in BBC3 expression during apoptotic signaling experiments.

Validation data demonstrates robust performance across multiple experimental platforms. Western blot analysis detects BBC3 in HeLa, MCF-7, Jurkat, and K562 cell lysates at dilutions between 1:500 and 1:2000, with an observed band at approximately 18 kDa. The slight difference from the predicted 21 kDa molecular weight likely reflects post-translational processing or protein conformation effects common with small BH3-only proteins. Immunohistochemistry staining has been validated in human gastric cancer and lung tissue sections, while immunofluorescence successfully localizes BBC3 in HepG2 cells. Flow cytometry applications have been confirmed using 786-O cells, providing flexibility for both fixed tissue and cell-based analyses.

This antibody supports investigations into apoptotic regulation, tumor suppressor pathways, and chemotherapeutic response mechanisms where BBC3 expression serves as a critical readout.